-
Beijing Airdoc Leads RMB 500 Million Joint Venture to Invest in AI-Powered Healthcare
•
Beijing Airdoc Technology Co., Ltd., a leading artificial intelligence (AI)-powered ophthalmology device company, has announced plans to invest RMB 250 million in the establishment of a joint venture (JV) with two Chinese investment firms. The JV, which will have a total capitalization of RMB 500 million, will focus on strategic…
-
Sirnaomics Receives FDA Feedback on STP705 Development Plan for isSCC Treatment
•
Sirnaomics Ltd (HKG: 2257), a leading biopharmaceutical company focused on the discovery and development of RNAi therapeutics, has announced receiving a written response from the U.S. Food and Drug Administration (FDA) regarding the required Class C meeting for STP705, a treatment for in situ squamous cell carcinoma (isSCC). The Class…
-
China Medical System’s Opzelura Approved in Macau for Vitiligo Treatment
•
China Medical System Holdings (CMS; HKG: 0867) has announced that it has received market approval in Macau for Opzelura (ruxolitinib) cream, a topical treatment indicated for patients aged 12 and above with non-segmental vitiligo involving the face. Opzelura, a topical Janus kinase (JAK) inhibitor, was initially approved in the U.S.…
-
Roche China’s Talent and Culture Vice President Chen Yanli Departs for New Opportunities
•
Roche (SWX: ROG), the Swiss pharmaceutical giant, has announced the departure of Chen Yanli, who served as Vice President of Talent and Organizational Culture at Roche China and Head of the Chinese Market Access Hospital Key Account Management Department. Chen has decided to leave Roche to pursue external development opportunities.…
-
Easton Pharmaceutical Gets NMPA Nod for Generic Version of Merck KGaA’s Concor
•
Easton Pharmaceutical Co., Ltd (SHA: 688513), based in Chengdu, has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its generic version of Concor, which contains bisoprolol and amlodipine, a compound preparation used as an alternative therapy for hypertension. The approval signifies that Easton’s…
-
Sanofi Advances Phase I/II Trial of Trifunctional NK Cell Engager in Blood Cancers
•
Sanofi (NASDAQ: SNY), a French multinational pharmaceutical company, has administered the first dose to a patient in the second part of a Phase I/II clinical trial for the trifunctional NK cell engager SAR443579, targeting blood cancers. The announcement was made by fellow French biotechnology company Innate Pharma (NASDAQ: IPHA) this…
-
Roche’s Columvi Meets Overall Survival Endpoint in Diffuse Large B-Cell Lymphoma Trial
•
Roche (SWX: RO), a leading Swiss pharmaceutical company, has announced that a late-stage clinical trial for its bispecific antibody Columvi (glofitamab) has successfully met its primary endpoint of overall survival (OS) in patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL). The trial involved patients who had received…
-
Novartis’s Fabhalta Shows Promise in Phase III IgA Nephropathy Trial
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced positive preliminary results from a Phase III clinical trial of its complement inhibitor Fabhalta (iptacopan) for the treatment of IgA nephropathy (IgAN). The trial data showed that after a nine-month treatment period, the Factor B inhibitor Fabhalta reduced proteinuria by 38.3% when…
